Fuchs endothelial corneal dystrophy: current perspectives

Gustavo Vedana, Guadalupe Villarreal Jr, Albert S Jun Wilmer Eye Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA Abstract: Fuchs endothelial corneal dystrophy (FECD) is the most common corneal dystrophy and frequently results in vision loss. Hallmarks of the disease incl...

Full description

Bibliographic Details
Main Authors: Vedana G, Villarreal Jr G, Jun AS
Format: Article
Language:English
Published: Dove Medical Press 2016-02-01
Series:Clinical Ophthalmology
Subjects:
Online Access:https://www.dovepress.com/fuchs-endothelial-corneal-dystrophy-current-perspectives-peer-reviewed-article-OPTH
id doaj-7e92013fd46e432992676b35f0f7a83d
record_format Article
spelling doaj-7e92013fd46e432992676b35f0f7a83d2020-11-25T01:30:59ZengDove Medical PressClinical Ophthalmology1177-54832016-02-012016Issue 132133025620Fuchs endothelial corneal dystrophy: current perspectivesVedana GVillarreal Jr GJun ASGustavo Vedana, Guadalupe Villarreal Jr, Albert S Jun Wilmer Eye Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA Abstract: Fuchs endothelial corneal dystrophy (FECD) is the most common corneal dystrophy and frequently results in vision loss. Hallmarks of the disease include loss of corneal endothelial cells and formation of excrescences of Descemet’s membrane. Later stages involve all layers of the cornea. Impairment of endothelial barrier and pump function and cell death from oxidative and unfolded protein stress contribute to disease progression. The genetic basis of FECD includes numerous genes and chromosomal loci, although alterations in the transcription factor 4 gene are associated with the majority of cases. Definitive treatment of FECD is corneal transplantation. In this paper, we highlight advances that have been made in understanding FECD’s clinical features, pathophysiology, and genetics. We also discuss recent advances in endothelial keratoplasty and potential future treatments. Keywords: Fuchs endothelial corneal dystrophy, corneal endothelial cell, corneal transplantation, Descemet’s stripping automated endothelial keratoplasty, Descemet’s membrane endothelial keratoplasty, endothelial keratoplastyhttps://www.dovepress.com/fuchs-endothelial-corneal-dystrophy-current-perspectives-peer-reviewed-article-OPTHFuchs endothelial corneal dystrophy (FECD)corneal endothelial cellcorneal transplantationDescemet stripping automated endothelial keratoplasty (DSAEK)Descemet membrane endothelial keratoplasty (DMEK)endothelial keratoplasty.
collection DOAJ
language English
format Article
sources DOAJ
author Vedana G
Villarreal Jr G
Jun AS
spellingShingle Vedana G
Villarreal Jr G
Jun AS
Fuchs endothelial corneal dystrophy: current perspectives
Clinical Ophthalmology
Fuchs endothelial corneal dystrophy (FECD)
corneal endothelial cell
corneal transplantation
Descemet stripping automated endothelial keratoplasty (DSAEK)
Descemet membrane endothelial keratoplasty (DMEK)
endothelial keratoplasty.
author_facet Vedana G
Villarreal Jr G
Jun AS
author_sort Vedana G
title Fuchs endothelial corneal dystrophy: current perspectives
title_short Fuchs endothelial corneal dystrophy: current perspectives
title_full Fuchs endothelial corneal dystrophy: current perspectives
title_fullStr Fuchs endothelial corneal dystrophy: current perspectives
title_full_unstemmed Fuchs endothelial corneal dystrophy: current perspectives
title_sort fuchs endothelial corneal dystrophy: current perspectives
publisher Dove Medical Press
series Clinical Ophthalmology
issn 1177-5483
publishDate 2016-02-01
description Gustavo Vedana, Guadalupe Villarreal Jr, Albert S Jun Wilmer Eye Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA Abstract: Fuchs endothelial corneal dystrophy (FECD) is the most common corneal dystrophy and frequently results in vision loss. Hallmarks of the disease include loss of corneal endothelial cells and formation of excrescences of Descemet’s membrane. Later stages involve all layers of the cornea. Impairment of endothelial barrier and pump function and cell death from oxidative and unfolded protein stress contribute to disease progression. The genetic basis of FECD includes numerous genes and chromosomal loci, although alterations in the transcription factor 4 gene are associated with the majority of cases. Definitive treatment of FECD is corneal transplantation. In this paper, we highlight advances that have been made in understanding FECD’s clinical features, pathophysiology, and genetics. We also discuss recent advances in endothelial keratoplasty and potential future treatments. Keywords: Fuchs endothelial corneal dystrophy, corneal endothelial cell, corneal transplantation, Descemet’s stripping automated endothelial keratoplasty, Descemet’s membrane endothelial keratoplasty, endothelial keratoplasty
topic Fuchs endothelial corneal dystrophy (FECD)
corneal endothelial cell
corneal transplantation
Descemet stripping automated endothelial keratoplasty (DSAEK)
Descemet membrane endothelial keratoplasty (DMEK)
endothelial keratoplasty.
url https://www.dovepress.com/fuchs-endothelial-corneal-dystrophy-current-perspectives-peer-reviewed-article-OPTH
work_keys_str_mv AT vedanag fuchsendothelialcornealdystrophycurrentperspectives
AT villarrealjrg fuchsendothelialcornealdystrophycurrentperspectives
AT junas fuchsendothelialcornealdystrophycurrentperspectives
_version_ 1725088521177268224